Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 211,135,786 papers from all fields of science
Search
Sign In
Create Free Account
CDX-110
Known as:
CDX 110
, CDX110
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
rindopepimut
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Act Investigators
2017
Corpus ID: 208350122
2016
2016
Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM.
A. Heimberger
,
G. Archer
,
+8 authors
J. Sampson
Journal of Clinical Oncology
2016
Corpus ID: 7062514
2021 Background: Unlike conventional therapies for GBM, immunologic targeting of tumor-specific gene mutations allows precise…
Expand
Highly Cited
2015
Highly Cited
2015
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
J. Schuster
,
R. Lai
,
+15 authors
J. Sampson
Neuro-Oncology
2015
Corpus ID: 27387166
BACKGROUND The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary…
Expand
Highly Cited
2015
Highly Cited
2015
107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma
D. Reardon
,
J. Schuster
,
+17 authors
J. Sampson
2015
Corpus ID: 79440195
Author(s): Reardon, DA; Schuster, JM; Tran, DD; Fink, KL; Nabors, LB; Li, G; Bota, DA; Lukas, RV; Desjardins, A; Ashby, LS; Duic…
Expand
Review
2015
Review
2015
IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA
D. Reardon
,
A. Desjardins
,
+17 authors
J. Sampson
2015
Corpus ID: 76083593
BACKGROUND: EGFRvIII, a constitutively active EGFR deletion driver mutation, is associated with poor long-term survival in…
Expand
2015
2015
Outcomes of the ACT III Study: Rindopepimut (CDX-110) Therapy for Glioblastoma.
B. Zussman
,
J. Engh
Neurosurgery
2015
Corpus ID: 39531213
G lioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Standard therapy, including maximal surgical…
Expand
2014
2014
IT-30ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA
D. Reardon
,
J. Schuster
,
+13 authors
J. Sampson
2014
Corpus ID: 76584854
BACKGROUND: EGFRvIII, a constitutively active tumorigenic EGFR deletion mutation, is linked to poor long-term survival. The…
Expand
2010
2010
Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).
R. Lai
,
L. Recht
,
+7 authors
J. Sampson
2010
Corpus ID: 74302009
2014 Background: EGFRvIII is a constitutively activated mutation of EGFR, not expressed in normal tissues but expressed in GBM…
Expand
Review
2009
Review
2009
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
A. Heimberger
,
J. Sampson
Expert Opinion on Biological Therapy
2009
Corpus ID: 42392725
Conventional therapies for glioblastoma multiforme (GBM) fail to target tumor cells exclusively, resulting in non-specific…
Expand
2008
2008
Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM
J. Sampson
,
G. Archer
,
+7 authors
A. Heimberger
2008
Corpus ID: 88357438
2011 Background: Conventional therapies for GBM fail to target tumor cells exclusively. Immunologic targeting of tumor- specific…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE